“The [5-item Asthma Control Questionnaire (ACQ-5)] score at 6 months in mepolizumab-treated patients was the best predictor of achieving clinical remission or clinical remission plus ...

Secondary end points were the annualized rate of asthma worsening, the annualized rate of severe exacerbations, the ACQ-5 score, and the forced expiratory volume in 1 second. Exploratory end ...

The change in ACQ-5 score showed a difference of 0.11 units (95% CI, 0.07 to 0.15) in favor of budesonide maintenance therapy. In patients with mild asthma, budesonide–formoterol used as needed ...

At 12 weeks, the least-squares mean change on the ACQ-5 was -0.70 and -0.85 points for the 800-mg and 1,200-mg rilzabrutinib groups, as compared with -0.12 and -0.31 points with placebo (nominal P ...